TIM
ATRS

Tortoise Investment Management’s Antares Pharma, Inc. ATRS Stock Holding History

Tortoise Investment Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-240
Closed – – 515
2016
Q1 		$0 Buy
+240
New +$232 ﹤0.01% 442

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLP
Pleasant Lake Partners Rincon, Puerto Rico $7.91M AUM 5.74% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Tortoise Investment Management's ATRS Position: Q2 2016 in Review

Tortoise Investment Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2016, closing a stake of 240 shares.

Tortoise Investment Management first reported a position in ATRS in Q1 2016 and held it in 1 quarter. The position peaked at $0 in Q1 2016. 71 funds tracked by Wall St. Rank hold ATRS as of Q2 2016.

  • Tortoise Investment Management reported no remaining Antares Pharma, Inc. position as of Q2 2016 after selling out during the quarter.
  • Tortoise Investment Management sold 240 Antares Pharma, Inc. shares in Q2 2016.
  • Tortoise Investment Management first reported a position in Antares Pharma, Inc. in Q1 2016 and held it in 1 quarter.
  • Tortoise Investment Management's Antares Pharma, Inc. position peaked at $0 in Q1 2016.
  • 71 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2016.

Based on Tortoise Investment Management's 13F filing for Q2 2016, filed 3 Aug 2016.